CureDuchenne Ventures 2020 Pitch Contest Submission Deadline: July 13, 2020!
Rewarding Rare Approaches to Treat Duchenne Muscular Dystrophy
SUBMISSIONS CLOSED
If you have any questions, please email pitch@cureduchenne.org
About the Contest:
- Open to colleges, universities, biotech companies and pharma companies in the United States with researchers at all career stages
- Focusing on new Duchenne therapeutics or therapeutic targets, or technology platforms that can help overcome current limitations of Duchenne therapies in development
- Finalists will have opportunity to pitch their idea to a panel of esteemed judges from the drug development and venture capital communities
- Email us at Pitch@CureDuchenne.org if you have any questions
The Winning Details:
- 2 Winners each receiving no-strings attached award of $25,000 by check made out to the winning college, university, or company
- Access to a wide array of experts in Duchenne drug discovery
- Ongoing mentoring from CureDuchenne lead scientists Mike Kelly, PhD & Lianna Orlando, PhD
Application Process
First Round:
Fill out application form and upload slide deck
Deadline July 13
Finalists selected
and notified
Week of August 3rd
Finalist round:
Finalists present 15 minute pitch to expert judging panel
August 17-21
Winners publicly
announced
October 2020
For over a decade, CureDuchenne Ventures has funded promising research that advances us toward a cure for Duchenne muscular dystrophy. For the first time, CureDuchenne is holding a competition to stimulate and support new, innovative ideas from a wide array of sources.
This competition is an opportunity for colleges, universities and biotech and pharma companies with outstanding scientists at all career stages to pitch their latest idea and potentially be rewarded with $25,000
SUBMISSIONS CLOSED
If you have any questions, please email pitch@cureduchenne.org
Cristina Csimma, PharmD, MHP
Chair of Board of Directors Caraway Therapeutics
Mitchell H. Finer, PhD
Chief Scientific Officer,
President of ElevateBio
Dave Greenwald, PhD
VP President, Business Development
Deerfield Management
Michael G. Kelly, PhD
Chief Scientific Advisor
CureDuchenne
Adam M. Koppel, MD, PhD
Managing Director
Bain Capital Life Sciences
Walter Kowtoniuk, PhD
Venture Partner
Third Rock Ventures
Martin Lehr
CEO
Context Therapeutics
Eric Olson, PhD
Professor & Chairman, Department of Molecular Biology
UT Southwestern Medical Center
Lianna Orlando, PhD
Senior Director of Research
CureDuchenne
Kush Parmar, MD, PhD
Managing Partner
5AM Ventures
SUBMISSIONS CLOSED
If you have any questions, please email pitch@cureduchenne.org
NO PURCHASE OR PAYMENT NECESSARY TO ENTER OR WIN. VOID IN PUERTO RICO AND WHERE PROHIBITED. Entrants must be either (a) an accredited college or university in the 50 United States or District of Columbia, or (b) a biotech or pharma company based in the 50 United States or District of Columbia. See application form, submission requirements, judging criteria, and official rules at CureDuchenne.org/pitchcontest. Entries must be submitted between 12:00 PM Eastern Time on 06/08/2020 and 4:00 PM Eastern Time on 07/13/2020. The two (2) eligible entrants with the most promising ideas in Duchenne Muscular Dystrophy therapy development will each win $25,000. Sponsor: CureDuchenne, located at 1400 Quail Street Suite 110, Newport Beach, CA 92660.